Sessions

All Sessions
keyboard_arrow_down
keyboard_arrow_down Show filters keyboard_arrow_up Hide filters
  • All Tracks
  • Atrium
  • Thames Hall
  • Cherwell
Conference & Exhibition Open
event_note Thursday, 17 Jun 2021
query_builder 8:00 - 18:00
card_travel Exhibition
mic English
Conference & Exhibition Open
Delegate Registration 8:00-9:30
Loading...
Thames Hall
Partnering
event_note Thursday, 17 Jun 2021
query_builder 8:30 - 9:30
card_travel Partnering
mic English
Please request meetings and book meetings via your HelloPartnering profile.
Loading...
Talent Drop-in Clinic
event_note Thursday, 17 Jun 2021
query_builder 9:30 - 11:00
card_travel Drop-in Session
mic English
Talent Drop-in Clinic
Loading...
Thames Hall
Welcome to BioForward 2020
event_note Thursday, 17 Jun 2021
query_builder 9:30 - 9:35
card_travel Technical Session
mic English
Welcome to BioForward 2020
Loading...
Thames Hall
Panel: Selecting the Right Board for your Business
event_note Thursday, 17 Jun 2021
query_builder 9:35 - 10:20
card_travel Panel Discussion
mic English
Panel: Selecting the Right Board for your Business
One of the biggest challenges for any company CEO is ensuring they appoint the right individuals to their Board, to achieve the best mix of requisite skills, experience and competencies that can guide and support the long-term success of the organisation.

The board will be responsible for many key decisions within the organisation including its control and accountability systems, final approval of the corporate strategy, risk management and legal compliance, approving and monitoring the progress of major capital expenditure, capital management, and acquisitions and divestitures.  

It is important that a potential Board member properly evaluates the organisation before committing, ensuring that their skills and experience fill a gap and compliment the other Board members.  

This panel will share information that will guide you on the key areas to consider when forming your board, and potential pitfalls to be aware of, including:

 
  • The importance of considering the composition of a board and the dynamics of its personalities; does the team have the patience and fortitude to work through pre-revenue phases?
  • Ensure you achieve a a good balance of values between scientific research and the commercial and financial skills and experience required to nurture the growth of a pre-revenue business
  • How will the Board be remunerated/rewarded for the considerable time they will devote to your organisation – what can be offered to board members instead of cash?
  • Are your Board members truly passionate about the science that is driving the company?
  • What is their attitude to risk?  A considered appetite for risk and an understanding of the commercialisation process, marketing, and business can be a great attribute.
  • How to deal with a conflict of interest - at board level in the life sciences industry there is generally a smaller pool of appropriate board candidates to choose from, so it is important to ensure all conflicts are declared and dealt with appropriately
  • Choose your Chair with care – it is important that they are highly experienced in the area you are specialising in, hold considerable gravitas in the industry and act as a respected figurehead for the business
Loading...
Thames Hall
Panel: What's New in the UK Regulatory Landscape?
event_note Thursday, 17 Jun 2021
query_builder 10:20 - 11:05
card_travel Panel Discussion
mic English
Panel: What's New in the UK Regulatory Landscape?
All company owners in the life sciences must maintain a comprehensive, real-time view of the regulations that exist in their industry and ensure that their compliance programs are full integrated into their evolving business strategies.
 

Regulatory matters must have a front and centre focus throughout the R&D process as well as when new business relationships are explored.  By ensuring you are fully compliant you are better supporting your teams and the ongoing work of your organisation.

This panel has been designed to review all that is new in the regulatory landscape of the life sciences industry; and as the UK looks forward to its future outside the EU,  we will also  address the key areas set to change or be impacted post the transition on 31st December 2020. 

Key topics will include:
  • An insight into the updates in the published Medicines and Medical Devices Bill – what does this mean for UK life sciences companies after we transition out of the EU, particularly regarding human medicines regulation, clinical trials, and medical devices
  • What are the the regulatory updates in areas such as using artificial intelligence in treatments?
  • How can the UK break new ground in complex clinical trials – will the implementation of new regulations make us a more attraction location for external companies?
  • What aspects of current bureaucratic processes can and should be modified, reduced or eliminated to make the UK system a faster, cheaper and more streamlined market?
Loading...
Thames Hall
Networking Break and Partnering Meetings
event_note Thursday, 17 Jun 2021
query_builder 11:10 - 11:30
card_travel Partnering
mic English
Networking Break and Partnering Meetings
Tea and coffee will be available in the Cotswold Foyer.

Please request meetings and book meetings via your HelloPartnering profile.
Loading...
BioLearn Masterclass: How the Drug Discovery Industry Works
event_note Thursday, 17 Jun 2021
query_builder 11:30 - 12:15
card_travel BioLearn Masterclass
mic English
BioLearn Masterclass: How the Drug Discovery Industry Works

This Masterclass will cover a brief overview of the following topics in a small group training-session:

  • The commercial landscape

  • Human biology, pathology and drug targets

  • Drug discovery and development

  • Industry pressures and responses

  • Industry in transition

Loading...
Thames Hall
Technical Session - Adaptive Design and Alternative Flexibility Levers for Clinical Trial Supply Chain Optimisation
event_note Thursday, 17 Jun 2021
query_builder 11:30 - 12:15
card_travel Technical Session
mic English
Technical Session - Adaptive Design and Alternative Flexibility Levers for Clinical Trial Supply Chain Optimisation

Adaptive Design and Alternative Flexibility Levers for Clinical Trial Supply Chain Optimisation


Innovation intensity has recently increased, from the development of the first biological drug  innovation has been shaping the future for our biopharmaceutical industry, one that will likely be very different from the past.  As a result, there is an increasing pursuit of flexibility in the supply chain in the quest for new medicines and vaccines. Flexibility can be defined as being responsive and adaptable to change at every stage of clinical trials. 
This session will discuss the importance of flexibility and the strategies by which it can be included into the clinical supply chain  – from adaptive design, protocol pooling and Just-in-Time (JIT).  It will explore benefits and limitations of these techniques.
Flexibility requires detailed planning and a thorough knowledge of the global dynamics (including country and site selection) that impact the supply chain from start to finish.

Adaptive design and alternative Flexibility levers for Clinical Trial Supply Chain Optimisation


Innovation intensity has recently increased, from the development of the first biological drug  innovation has been shaping the future for our biopharmaceutical industry, one that will likely be very different from the past.  As a result, there is an increasing pursuit of flexibility in the supply chain in the quest for new medicines and vaccines. Flexibility can be defined as being responsive and adaptable to change at every stage of clinical trials. 
This session will discuss the importance of flexibility and the strategies by which it can be included into the clinical supply chain  – from adaptive design, protocol pooling and Just-in-Time (JIT).  It will explore benefits and limitations of these techniques.
Flexibility requires detailed planning and a thorough knowledge of the global dynamics (including country and site selection) that impact the supply chain from start to finish.

Loading...
Thames Hall
Technical Session - Strategies to Consider when Developing your Injectable Drug Product for Clinical Trials
event_note Thursday, 17 Jun 2021
query_builder 12:15 - 13:00
card_travel Technical Session
mic English
Technical Session - Strategies to Consider when Developing your Injectable Drug Product for Clinical Trials

The sterile injectables market is seeing a consistent growth increase in revenue demand driven by the growth for of biological therapies.  In 2015, this market was valued at $299.7 billion; and its growth rate is projected at 6.9 percent, at least through the year 2024. There are several end-product formats to choose from for companies when developing sterile injectable drugs. The most common ones formats are liquid or lyophilized vials, pre-filled syringes, and cartridges. .  The most desired form is normally an aqueous liquid which can be stored at room temperature, however, there are many perfectly acceptable products which are supplied in solid form such as lyophilised powder for reconstitution, or need to be stored in refrigerated or even frozen conditions.  To make the right choices which can, and arguably should, change during the development life cycle of the product, the pharmaceutical scientist needs to employ a sound development strategy.  In this conference the choices available and strategies which can be employed at the different stages of development will be described.

Loading...
Processing. Please wait.
Loading...